Cytotoxic Agents
Cytotoxic agents are drugs that act directly on DNA or RNA synthesis or on cell division, halting the abnormal proliferation of epidermal cells, immune cells (B and T lymphocytes) and inflammatory cells. Although they were first developed for cancer chemotherapy, at much lower concentrations and doses they play a key role in clinical dermatology. They are used to control chronic benign proliferative skin disease (severe psoriasis), serious autoimmune blistering diseases (pemphigus, pemphigoid), mycosis fungoides and inflammatory skin conditions that do not respond to corticosteroids.
At Haute-Derma, using cytotoxic drugs requires strict toxicity monitoring, with assessment of bone marrow, liver and kidney function before and throughout treatment, so that patients get the full therapeutic benefit while staying safe.
Biological Mechanisms and Pharmacodynamics
Antimitotic Effects and DNA Damage
Cytotoxic drugs disrupt the cell cycle, particularly the S and M phases, through several specific biochemical pathways:
- Inhibition of folate and nucleotide synthesis (S phase): Methotrexate (MTX) binds to and competitively, reversibly inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate. This interrupts purine and thymidylate synthesis, stalling DNA synthesis and cell division.
- DNA alkylating agents (non-specific / phase-specific): Cyclophosphamide is activated in the liver to phosphoramide mustard, which forms cross-links between the two DNA strands (interstrand cross-links) or within a single strand. This breaks the DNA and triggers programmed cell death (apoptosis).
- Inhibition of de novo purine synthesis: Azathioprine (converted to 6-mercaptopurine) and mycophenolate mofetil (MMF, an inhibitor of inosine monophosphate dehydrogenase) shut down the purine synthesis pathway. Their effect is selective for B and T lymphocytes, which depend entirely on this pathway.
- Inhibition of the mitotic spindle (M phase): Vinblastine or bleomycin either damage DNA directly or bind to tubulin, preventing formation of the microtubules needed for cell division.
Immunosuppressive and Anti-Inflammatory Effects in Dermatology
- Fewer and less active T and B lymphocytes: They suppress the explosive proliferation of autoreactive T and B cells attacking the epidermis, basement membrane or dermal structures.
- Less white-cell accumulation: They reduce neutrophil chemotaxis and the release of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6).
Common Cytotoxic Drugs Used in Dermatology
Antimetabolites
- Methotrexate: First choice for moderate-to-severe plaque psoriasis, psoriatic arthritis, refractory atopic dermatitis and dermatomyositis.
- Azathioprine (AZA): Preferred for pemphigus vulgaris, bullous pemphigoid and severe allergic contact dermatitis.
- Mycophenolate mofetil (MMF): An effective alternative to azathioprine with less bone marrow toxicity, used in autoimmune blistering diseases and discoid lupus erythematosus.
Alkylating Agents
- Cyclophosphamide: Reserved for life-threatening conditions or failure of other cytotoxic drugs, such as severe autoimmune blistering disease, necrotizing vasculitis and rapidly progressive autoimmune dermatomyositis.
Other Agents and Topical Forms
- Fluorouracil (topical 5-FU 5%): Applied to actinic keratoses, Bowen's disease (squamous cell carcinoma in situ) and stubborn warts.
- Mechlorethamine / carmustine (topical): Used to treat cutaneous T-cell lymphoma (mycosis fungoides, stages IA–IIA).
Comparing Cytotoxic Drugs in Dermatology
| Drug (Generic) | Main Dermatologic Indications | Toxicity |
|---|---|---|
| Methotrexate | Moderate-to-severe psoriasis, psoriatic arthritis | Bone marrow toxicity, liver toxicity (cirrhosis), interstitial pneumonitis |
| Azathioprine | Pemphigus, pemphigoid, severe atopic dermatitis | Bone marrow suppression (leukopenia), liver toxicity, higher toxicity risk with TPMT deficiency |
| Mycophenolate mofetil | Pemphigus, cutaneous lupus, scleroderma | Gastrointestinal upset (diarrhea), mild neutropenia |
| Cyclophosphamide | Necrotizing vasculitis, refractory pemphigus | Hemorrhagic cystitis, severe bone marrow failure, risk of infertility |
| Fluorouracil (5-FU) | Actinic keratosis, Bowen's disease | Severe local irritation, redness, painful erosions |
Managing Toxicity and Safety Monitoring
Cytotoxic drugs always carry a risk of serious systemic side effects if they are not monitored properly:
- Bone marrow suppression: Can cause pancytopenia, neutropenia leading to life-threatening opportunistic infections, or thrombocytopenia with bleeding.
- Liver toxicity and cirrhosis (hepatotoxicity): A particular concern with long-term methotrexate. Folic acid (5 mg/week) is given on a non-methotrexate day to reduce blood and gastrointestinal toxicity without weakening the effect on psoriasis.
- Checking TPMT before starting azathioprine: The enzyme thiopurine S-methyltransferase (TPMT) metabolizes azathioprine. Patients with inherited TPMT deficiency build up toxic 6-thioguanine nucleotides (6-TGN), which can cause dangerous acute bone marrow failure.
- Hemorrhagic cystitis: Caused by acrolein, a cyclophosphamide metabolite, collecting in the bladder. Patients should drink plenty of fluids, and mesna is added as a bladder protectant at high doses.
Treatment Protocol at Haute-Derma
Comprehensive Pre-Treatment Baseline Workup
- Complete blood count, reticulocytes and platelets.
- Liver function (AST, ALT, bilirubin, albumin) and kidney function (urea, creatinine, eGFR).
- Screening for latent infections: hepatitis B (HBsAg, anti-HBc), hepatitis C (anti-HCV), tuberculosis (QuantiFERON-TB Gold) and HIV.
- TPMT enzyme activity (if azathioprine is planned) or FibroScan/PIIINP to assess liver fibrosis (if methotrexate is planned).
- A confirmed negative pregnancy test and a commitment by both men and women to use reliable contraception during and after treatment.
Dosing and Initiation
- Methotrexate: Taken as a single dose once a week (usually starting at 7.5–15 mg/week), never daily. Folic acid 5 mg is added 24–48 hours after the MTX dose.
- Azathioprine: Starting at 1–2.5 mg/kg/day depending on TPMT activity.
- Mycophenolate mofetil: Starting at 1–2 g/day in two divided doses.
Routine Monitoring Schedule
- Complete blood count and liver/kidney function every 2 weeks for the first 2 months, then every 1–3 months.
- Stop or reduce the dose immediately if the white cell count falls below 3,000/µL, platelets fall below 100,000/µL, or liver transaminases rise above 3 times the upper limit of normal.
